Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare
Soligenix Inc., formerly known as DOR BioPharma Inc., a late-stage biotechnology company, today announced it has formed a consortium to develop technology to enhance acting vaccines, including RiVax, the company’s proprietary vaccine for ricin toxin, which can be used as a biological weapon. Soligenix also announced it was awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to continue this work. The announced consortium draws together industry and academic researchers from various disciplines, including the University of Colorado, the University of Kansas, and the Tulane…